Methods: 1110 eyes of 1110 patients were included in this retrospective study. 726 eyes had DME, 262 eyes had macular edema secondary to branch retinal vein occlusion, and 122 eyes had macular edema secondary to central retinal vein occlusion. Data were collected at baseline, and each monthly visit. All adverse events during DI injection and during 6-month follow-up were recorded. IOP was measured at baseline and each visit.

Results: The mean ages was 61.6±8.5 year (range: 22-88 years). There was no signifi cant differences in mean IOP measurements among values taken prior to injection and during each monthly visit afterward (p>.050). 168 eyes had IOP values of more than 20 mmHg during the follow-up period in general. 98 eyes did not receive any treatment, 65 eyes were treated with topical drops. 5 eyes were treated with selective laser trabeculoplasty. No surgery was required for any patient. No systemic adverse event observed.

Conclusion: DI injection may not carry a big risk of IOP rising in fi rst 6 months. Also there may be no systemic adverse events associated with DI injection in fi rst 6 months. Keywords : corticosteroids, dexamethasone implant, diabetic macular edema, intravitreal injection, retinal vein occlusion